About UsResearch & DevelopmentBusinessInvestor RelationsIndustry Info

About Us
 
Mergers & Acquisitions

Mergers

To make Marksans Pharma Ltd. completely integrated what was missing were operations in API and Bulk drugs. Merger of TASC Pharma with Marksans filled in this gap.

TASC was listed on the Mumbai and National Stock Exchanges in 1993 and 2002 respectively. TASC operated large bulk drugs and API manufacturing facilities in Pune that are compliant with CGMP standards and are expected to receive US FDA clearances. TASC's main areas of production were anti-ulcerants and anti-infectives for clients in the domestic market and overseas export markets.

Acquisitions
Nova Pharmaceuticals
Marksans acquired an Australian marketing company - Nova Pharmaceuticals ("NP") in 2005. NP specializes in R&D and marketing of generic pharma products & has robust operating margins. It currently has a basket of 14 products, with additional 25 products filed for TGA approvals. NP has presence in the top pharmacies and major chain stores for the supply of generics and OTC.
Hale Group
Company acquired UK's Hale Group along with its subsidiary company Bell Sons & Co ("Bel") in the year 2008. Hale group is equally owned via the holding company by Philip Hale and Linda Shepherd. Bell is a well-established manufacturer of a broad range of OTC pharmaceuticals having full approval of the UK MHRA and currently holds 38 product licences. Licensed products contribute over 45% of Bell 's total turnover. Bell manufactures licensed products both as own branded products and, for certain customers, in own label form together with a range of unlicensed products. Customers include retailers, pharmacies, chemist wholesalers and cash and carry outlets. The company employs 106 people at its freehold licensed manufacturing site in Southpor, Merseyside and has further 12 employees providing sales administration, buying and technical support. The company had clocked a turnover of £ 8.03 million and £ 8.94 million respectively for FY'05 and FY'06 (year ending December). The EBITDA margins for the said period stand at 12% and 14% respectively.

The Company's products baskets consists of:

Cough and cold remedies
Galenicals
Vitamins
Palliative and healthcare items
Oils
Antiseptics and disinfectants
 
The Company has been in the export markets for more than 80 years now. Its products are well recognised and respected in the overseas markets. The company products are sold in more than 40 countries. Key markets are West Africa and Middle East.


 

 

 

 


 

 

 

 



 © Copyright 2008 Marksans Pharma.